Login

Financial Snapshot

Revenue
TTM
$9.346M
Gross Margin
TTM
44.72%
Net Income
TTM
$6.375M
Current Assets
2024 Q2
Current Liabilities
2024 Q2
Current Ratio
2024 Q2
1667.04%
Total Assets
2024 Q2
Total Liabilities
2024 Q2
Book Value
2024 Q2
$13.75M
Cash
2024 Q2
P/E
TTM
0.6824
Free Cash Flow
TTM
-$2.838M

Stock Price

Loading...
Market Cap: $4.35 Million

About Guardion Health Sciences, Inc.

Guardion Health Sciences, Inc. engages in the business of developing and distributing clinically supported nutrition, medical foods, and dietary supplements. The company is headquartered in Houston, Texas and currently employs 9 full-time employees. The company went IPO on 2019-04-05. The firm offers a portfolio of science-based, clinically supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients. The firm sells two ocular products: GlaucoCetin and Lumega-Z. GlaucoCetin is a dietary supplement in a capsule form designed specifically to provide nutrients to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health. Lumega-Z, its medical food product, has a formula designed to replenish and restore the macular protective pigment, simultaneously delivering critical and essential nutrients to the eye. As a medical food, Lumega-Z must be administered under the supervision of a physician or professional healthcare provider. The company sells GlaucoCetin and Lumega-Z on its Website, guardionhealth.com.

Industry: Pharmaceutical Preparations Peers: SMART FOR LIFE, INC. CV Sciences Inc Estee Lauder Companies Inc Genufood Energy Enzymes Corp. KONA GOLD BEVERAGE, INC. LiveWire Ergogenics, Inc. RELIV INTERNATIONAL INC

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support